股票代码：002044.SZ 股票简称：美年健康 上市地点：深圳证券交易所 美年大健康产业控股股份有限公司 发行股份购买资产暨关联交易 报告书（草案）（修订稿） | 项目 | 交易对方 | | --- | --- | | | 刘三宝、刘菊香、桂嘉男、吴雪彦、吕雪珍、吴星明、黄荣、程景森、 郑超、周涛、程绍举、刘景平、南通美富、上海宝思来、孙嘉凯、李 | | 发行股份购买资产 | | | 暨关联交易 | 建国、海南丰誉、刘广、李红、张伟、绍兴柯美、许其玉、李冬秋、 | | | 甘泉、李京贞、郭美钦、冯霞芳、林峣、张燃、冯利松、杜海霞、张 | | | 乾、杜宏、研计公司、赵国荣、孟祥怀、卢秀梅等共 名交易对方 37 | 独立财务顾问 二〇二五年九月 声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、上市公司声明 本公司及本公司全体董事、监事、高级管理人员保证为本次交易所提供的有 关信息的真实性、准确性、完整性，不存在任何虚假记载、误导性陈述或者重大 遗漏，并对所提供信息、出具的说明及确认的真实性、准确性、完整性承担相应 的法律责任。如因提供的信息、出具的说明及确认存在虚假记载、误导性陈 ...

美年大健康产业控股股份有限公司（以下简称"公司"）拟通过发行股份的方 式购买交易对方持有的衡阳美年健康体检中心有限公司 84.00%股权、宁德美年大 健康管理有限公司 81.00%股权、烟台美年大健康体检管理有限公司 75.00%股权、 烟台美年福田健康体检管理有限公司 49.00%股权、武汉美慈奥亚科技管理有限公 司 52.81%股权、三明美年大健康管理有限公司 85.00%股权、肥城美年健康管理有 限公司 90.00%股权、德州美年大健康体检管理有限公司 84.00%股权、连江美年大 健康管理有限公司 82.00%股权、沂水美年大健康体检管理有限公司 80.50%股权、 山东美铭奥亚健康咨询有限公司 92.35%股权及公司控股子公司郑州美健健康管理 有限公司 47.37%少数股权、广州花都区美年大健康管理有限公司 49.00%少数股权、 安徽美欣健康管理咨询有限公司 42.46%少数股权、淄博美年大健康管理有限公司 49.00%少数股权、吉林市昌邑区美年大健康科技管理有限公司 48.05%少数股权 （以下简称"本次交易"）。 公司于 2025 年 8 月 22 日收到深圳证券交易所出具的《关于美年大健康产 ...

二、监事会会议审议情况 证券代码：002044 证券简称：美年健康 公告编号：2025-064 美年大健康产业控股股份有限公司 第八届监事会第三十三次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 美年大健康产业控股股份有限公司（以下简称"公司"）第八届监事会第三十 三次（临时）会议经全体监事同意，会议于 2025 年 9 月 19 日上午 10:30 以书面 审议方式召开。应出席本次会议的监事 3 名，实际出席会议的监事 3 名。本次会 议的召开符合《中华人民共和国公司法》《公司章程》及有关法律、法规的规定。 监 事 会 二〇二五年九月二十日 1、审议并通过《关于公司签署<美年大健康产业控股股份有限公司与研计 （上海）企业管理有限公司之盈利预测补偿协议之补充协议>的议案》 表决结果：赞成 3 票，反对 0 票，弃权 0 票。 公司对与研计（上海）企业管理有限公司（以下简称"研计公司"）签署的《盈 利预测补偿协议》进行调整，符合公司及研计公司的实际情况，符合《监管规则 适用指引——上市类第 1 号》之"1-2 业绩 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-063 美年大健康产业控股股份有限公司 第九届董事会第十二次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 美年大健康产业控股股份有限公司（以下简称"公司"）第九届董事会第十二 次（临时）会议经全体董事同意，会议于 2025 年 9 月 19 日上午 10 时以书面审议 方式召开。应出席本次会议的董事为 9 名，实际出席会议的董事为 9 名。本次会 议的出席人数、召开表决程序、议事内容均符合《中华人民共和国公司法》《公 司章程》等有关规定。 二、董事会会议审议情况 为保障公司及中小股东利益，同意公司与业绩承诺方研计（上海）企业管理 有限公司签署《盈利预测补偿协议之补充协议》，对《盈利预测补偿协议》的协 议变更及不可抗力等条款进行调整。 本议案已经公司第九届董事会独立董事专门会议第五次会议审议通过，并同 意提交董事会审议。根据公司 2025 年第一次临时股东大会对董事会的授权，本议 案无需提交股东大会审议。 表决结果：赞成 6 票，反对 0 票，弃权 0 ...

Core Viewpoint - Meinian Health's stock price has shown fluctuations, with a year-to-date increase of 12.52% but a recent decline of 2.65% over the last five trading days, indicating volatility in investor sentiment [2]. Financial Performance - For the first half of 2025, Meinian Health reported a revenue of 4.109 billion yuan, a year-on-year decrease of 2.28%, and a net profit attributable to shareholders of -221 million yuan, down 2.59% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 634 million yuan, with 127 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 18, Meinian Health's stock price was 5.15 yuan per share, with a market capitalization of 20.158 billion yuan. The stock experienced a net outflow of 53.52 million yuan in principal funds [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on February 19, where it recorded a net buy of -155 million yuan [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 8.95% to 172,400, while the average circulating shares per person increased by 9.87% to 22,471 shares [2]. - The top ten circulating shareholders include Huabao Zhongzheng Medical ETF, which increased its holdings by 1.9034 million shares, and a new entry,招商优势企业混合A, holding 60 million shares [3].

Core Insights - The collaboration between 港仔机器人集团 and 美年健康 marks a significant shift in the global health industry, introducing AI-driven health services through a strategic partnership valued at over 800 million yuan [1][5]. Group 1: Partnership Overview - The partnership aims to deploy 20,000 "smart health robot examination centers" over the next three years, transforming health services by making them more accessible and convenient for the public [2][4]. - This initiative will create a vast "human-machine collaborative health service network," allowing individuals to receive health assessments in their workplaces, communities, and factories [2][4]. Group 2: Technological Integration - 港仔机器人的 advanced humanoid robots will integrate over 30 instant detection functions, providing comprehensive health data collection, while 美年健康 will leverage its expertise to analyze this data and offer personalized health plans [3][4]. - The "海睿OS" cloud-based medical brain will enable real-time data processing for millions of users, addressing healthcare disparities by providing high-quality health guidance even in remote areas [3][5]. Group 3: Market Impact - The collaboration combines 美年健康's extensive network of over 500 clinics and a large customer base with 港仔机器人的 cutting-edge technology, creating a differentiated service system in health management [4]. - This partnership is expected to reach 300,000 corporate users and millions of individual users, establishing a new standard for AI in healthcare and showcasing China's capabilities in the global medical AI landscape [5].

Core Viewpoint - The partnership between 港仔机器人 and 美年健康 marks a significant advancement in the integration of AI technology into health management, aiming to create a large-scale health service network utilizing intelligent robots [1] Company Summary - 港仔机器人 experienced a stock price increase of nearly 12% at the close, finishing up 5.43% at 1.36 HKD, with a trading volume of 25.586 million HKD [1] - The company has successfully delivered 1,000 quadruped robots to 香港通宏护卫, demonstrating its recognized commercial viability in the market [1] Industry Summary - The strategic cooperation agreement signed between 港仔机器人 and 美年健康 is valued at over 800 million RMB, representing a historic breakthrough in the health management sector with the introduction of "AI proactive health protection" [1] - Over the next three years, the partnership plans to deploy 20,000 "smart health robot examination centers," aiming to establish the largest "human-machine collaborative health service network" globally [1]

Group 1 - The core viewpoint of the article highlights the strategic partnership between 港仔机器人 (00370) and 美年健康 (002044.SZ), which is expected to leverage their respective strengths in the health management sector [1] - 港仔机器人 experienced a significant stock price increase, closing up 5.43% at 1.36 HKD, with a trading volume of 25.586 million HKD [1] - The partnership involves a commercial contract valued at over 800 million HKD, marking a historic breakthrough in integrating "embodied intelligent humanoid robots" with medical AI models into the health management field [1] Group 2 - 美年健康 operates over 500 offline branches and has a customer base in the millions, providing a nationwide channel network for the collaboration [1] - 港仔机器人 has successfully delivered 1,000 quadruped robots to Hong Kong Tonghong Security, demonstrating its recognized commercial deployment capabilities [1] - Over the next three years, the two companies plan to deploy 20,000 "smart health robot examination centers," creating the largest "human-machine collaborative health service network" globally [1]

Core Insights - The collaboration between Hong Kong-based Portai Robotics and China's Meinian Health marks a significant shift in the global health industry, introducing AI-driven health management solutions through a strategic partnership valued at over 800 million yuan [1][5]. Group 1: Innovative Health Management - The partnership aims to address traditional health management challenges by deploying 20,000 "smart health robot examination centers" over the next three years, making health services more accessible and proactive for individuals [2][4]. - This initiative will create a "15-minute accessible health examination circle," allowing employees and community members to receive health assessments conveniently [2][4]. Group 2: Technological Integration - The collaboration combines Portai Robotics' advanced humanoid robots with Meinian Health's medical expertise, enabling comprehensive health management from detection to rehabilitation [3][4]. - Portai's humanoid robots feature over 30 instant detection functions and are supported by the "Huirui OS" cloud-based medical brain, which can analyze health data in real-time and provide personalized health recommendations [3][5]. Group 3: Strategic Synergy - The partnership leverages Meinian Health's extensive network of over 500 clinics and a large customer base, enhancing the reach of smart health services [4]. - Portai Robotics' technological capabilities complement Meinian Health's market presence, creating a differentiated service system that benefits both companies and their customers [4][5]. Group 4: Global Impact - This collaboration signifies a milestone in China's export of intelligent medical paradigms, establishing a new standard for global medical AI [5]. - The deployment of 20,000 smart examination centers is expected to reach 300,000 corporate users and millions of individual users, contributing to a significant accumulation of health data and setting a benchmark for future health management solutions [5].

Group 1 - The core viewpoint of the collaboration between 港仔机器人集团 and 美年健康 is the establishment of a strategic partnership to revolutionize the health management industry through the integration of humanoid robots and AI medical models, marking a significant milestone in proactive health services [2][7] - The partnership involves the deployment of 20,000 "smart health robot examination centers" over the next three years, aiming to create the largest "human-machine collaborative health service network" globally, making health assessments more accessible [3][5] - 港仔机器人的 humanoid robots are equipped with over 30 instant detection functions, enabling comprehensive health data collection, while the "海睿OS" cloud medical brain analyzes this data to provide personalized health plans [4][6] Group 2 - The collaboration represents a "super complementary" relationship, leveraging 美年健康's extensive offline network of over 500 clinics and 港仔机器人的 advanced technology to enhance the reach and quality of intelligent health services [5][6] - This partnership is not just a commercial agreement but a significant step in defining a new global standard for medical AI, showcasing China's capability in smart healthcare solutions [6][7] - The initiative is expected to reach 300,000 corporate users and millions of individual users, contributing to the accumulation of health data and establishing a unique competitive advantage in the healthcare sector [7]